PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

neuroblastoma prognosis

18F-FDG PET/CT radiomics nomogram provides detailed insight into neuroblastoma

Better risk stratification can improve clinical decision making and better outcomes, experts involved in the study explained in EJR.

July 21, 2022
Organs

New PET imager cleared for U.S. sales

A Canadian manufacturer of positron emission tomography equipment has received FDA’s OK to market a small-footprint scanner that images targeted organs bearing radiotracers at close range.

July 20, 2022
health_insurance_family.png

Big private payer reverses course on cardiac PET/CT coverage

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

July 1, 2022
Dementia

CMS initiates official review of PET scan limit for patients with Alzheimer's

"Clinical study protocols may involve more than one PET [amyloid-beta] scan per patient,” the CMS announcement said.

June 28, 2022
lung cancer pulmonary nodule chest

Preoperative PET/CT imaging linked with better survival in advanced lung cancer

PET/CT imaging in these patients increases overall survival depending on the cancer’s stage, with those diagnosed with stage 3A and 3B NSCLC appearing to benefit the most from the exam. 

June 24, 2022
U.S. News & World Report children’s hospitals cardiology heart surgery

Lower doses, faster acquisitions: Experts share how to improve PET scans for peds

This week in AJR, experts shared how they were able to reduce FDG PET scan acquisition times by 33%, thus reducing the amount of total radiation exposure to more vulnerable pediatric patients. 

June 22, 2022
The American Medical Association (AMA) Board of Delegates approved a policy calling on payers to reimburse for the drug regadenoson and not to employ payment policies that push for cardiologists to change the drug they use for pharmacologic stress for one that is considered less safe. The policy was adopted at the AMA 2022 meeting. #AMA #AMA175 #AMAmtg #ASNC

AMA supports reimbursement for pharmacologic stress agent regadenoson

The American Medical Association Board of Delegates approved a policy calling on payers to reimburse for the drug regadenoson and not to employ payment policies that push for cardiologists to change the drug they use for pharmacologic stress for one that is considered less safe.

June 22, 2022
SNMMI Image of the Year 68Ga-FAPI-46 PET/CT heart attack acute myocardial infarction

‘Image of the Year’ highlights the predictive power of a new PET imaging agent

The Society of Nuclear Medicine and Molecular Imaging has chosen its 2022 Image of the Year, and it’s one that is sure to interest anyone in the field of cardiac imaging.

June 15, 2022

Around the web

The newly approved AI models are designed to improve the detection of pulmonary embolisms and strokes in patients who undergo CT scans.

"I see, at least for the next decade, this being a SPECT and PET world, not one or the other," explained Tim Bateman, MD.

The FDA-approved technology developed by HeartFlow can predict a patient's long-term risk of target vessel failure as well as more invasive treatments performed inside a cath lab. 

Trimed Popup
Trimed Popup